1. Chronic prostatitis and chronic pelvic pain syndrome: a new consensus guideline

Chronic prostatitis and chronic pelvic pain have a significant impact on patients’ quality of life and there is currently a lack of robust published evidence and guidance on how to recognise and manage the conditions, particularly for practitioners working in primary care. Prostate Cancer UK put together a Prostatitis Expert Reference Group (PERG) to develop a consensus guideline to help address this. The consensus guideline is now available in a peer-reviewed publication as an open-access article (here). Additional information and documents relating to the consensus guidelines can also be found on the Prostate Cancer UK website (here).

2. Review of recent findings in young-age prostate cancer

A review, by Hussein and Colleagues from Canada, looked to identify characteristic features of prostate cancer in men at young age as opposed to prostate cancers identified in older men. The authors highlighted findings including that young-age prostate cancer has several biological and genetic features, distinct from elderly-onset prostate cancer. They also suggested that most patients with prostate cancer at a young age tend to have low-grade and stage disease compared with elderly-onset prostate cancer. Other take home messages the authors reported included BRCA2 mutation carriers have an increased risk of early-onset prostate cancer with a more aggressive biology.

3. Evolutionary history of prostate cancer

Gundem et al. looked at how the disease spreads around the body, and how it evolves to become resistant to treatment. The authors used whole-genome sequencing to characterise multiple metastases arising from prostate tumours. Cancer Research UK have written an in-depth science blog about the research the group have carried out: Migration, settlement, and more migration: how prostate cancers spread.

4. Protein that may signal more aggressive prostate cancers

University of Michigan researchers, Ge et al., previously discovered a regulatory mechanism in bone cells, Runx2. In a recent paper they published in the journal Oncogene they reported these biomarkers seemed to play a crucial role in the rapid growth of tumours, and highlighted its value as a potential diagnostic marker and therapeutic target.

Health professional news archive